US modeling study · CSL Seqirus authors · Adults 50-64

Adjuvanted flu: not just a 65+ vaccine anymore?

New US modeling puts a number on extending adjuvanted influenza vaccine (aTIV/aQIV) use down to age 50 - just as Moderna's mRNA-1010 and Sanofi's Fluzone HD both pursue regulatory pathways into the very same age band.

McGovern I, Flores R, Haag MDM. Potential to Avert Additional Influenza Burden in the United States with Use of Adjuvanted vs. Standard Influenza Vaccines in Individuals 50-64 Years of Age. Vaccines 2026;14(5):380. PMID 42188753. Sample from MarketVIEW: Seasonal influenza vaccines (CAT VAMV036).

15.2%
avg. seasonal burden averted
per +5% rVE gain, ages 50-64
172,738
symptomatic illnesses averted
per +5% rVE gain (avg./season)
1,832
hospitalizations averted
per +5% rVE gain (avg./season)
105
deaths averted
per +5% rVE gain (avg./season)
Latest · 2026

The timing is not a coincidence. Days after the FDA's VRBPAC voted 9-0 on 18 June 2026 that Moderna's mRNA-1010 (mFLUSIVA) benefits outweigh its risks for adults 50+, this CSL Seqirus-authored modeling makes its own quantified case for widening adjuvanted vaccine use into the same 50-64 age band. Moderna's own regulatory path splits by age - traditional approval built on direct efficacy for 50-64, accelerated approval leaning on immunogenicity for 65+ - almost a mirror image of where the hard evidence currently sits for adjuvanted vaccines. FDA decision (PDUFA) due 5 August 2026. Sanofi has its own move in motion too: the FDA and EMA have accepted for review its submission to extend Fluzone High-Dose/Efluelda to adults 50 and above, backed by a completed head-to-head Phase 3 trial - though the company's own guidance points to a regulatory decision around 2027.

Finding 01 - The established case

In adults 65+, adjuvanted vaccines already outperform standard dose

The MF59-adjuvanted influenza vaccine (aTIV/aQIV) was designed to boost the immune response of older adults, and the real-world evidence backs it up: among adults aged 65 and over, aTIV/aQIV has shown 14% greater relative vaccine effectiveness than standard-dose TIV/QIV. That comparative-effectiveness base is broad, direct, and already built into ACIP guidance and payer coverage - it is the evidence bar this new study is trying to extend down to a younger population.

One reveal This new study does not test adjuvanted vaccines head-to-head in 50-64-year-olds. It extrapolates the 65+ effectiveness advantage into a younger age band using a CDC-based static compartmental model - modeling, not a clinical trial.
Finding 02 - The modeled case for 50-64

Every +5 points of relative effectiveness compounds into a measurable public health return

Modeling five US influenza seasons, the authors found that on average, each 5-percentage-point increase in the relative effectiveness of aTIV/aQIV vs. standard QIV prevented an additional average seasonal incremental burden of 15.2% (range 5.9%-37.2% across the seasons modeled). In absolute terms, per +5% rVE gain, that averages out to:

01
Symptomatic illnesses
172,738
02
Outpatient visits
74,277
03
Hospitalizations
1,832
04
ICU admissions
343
05
Deaths
105

Bars indicate relative rank across outcomes, not a shared linear scale - figures span more than three orders of magnitude. All values are US, average per season, per +5% rVE gain.

One reveal 105 deaths averted per +5% rVE gain sounds modest - but the modeled rVE gain of aTIV/aQIV vs. standard dose ranges up to 37.2%. Scaled across that range, the seasonal averted-death estimate could run into the hundreds nationally.
Finding 03 - Where the risk sits

A modeled case, published by the market leader, right as the age line moves

Deterministic sensitivity analysis found the greatest variability was tied to relative vaccine effectiveness and underlying burden estimates - exactly the two inputs a modeling exercise cannot observe directly. Probabilistic sensitivity results were normally distributed, which supports the central estimate but does not substitute for head-to-head efficacy data in this age band.

Adults 65+
14%
Established. Direct comparative-effectiveness evidence vs. standard-dose vaccines; the basis for current ACIP & payer positioning.
Adults 50-64
15.2%
Emerging. Average incremental burden averted per +5% rVE gain - modeled and extrapolated, not measured head-to-head.
Full disclosure
CSL Seqirus
All three authors are CSL Seqirus employees. CSL Seqirus markets FLUAD/aTIV - the very product this modeling argues should be used more widely.
One reveal Adjuvanted vaccines have no current ACIP recommendation or FDA licensure in the 50-64 age band. This paper is best read as the opening argument for a label and guideline expansion - not as evidence that expansion has happened.
Finding 04 - The three-way race

Three manufacturers, three evidence bases, three different clocks

This CSL Seqirus paper does not stand alone. By mid-2026, three of the largest players in US influenza vaccines were simultaneously pursuing the 50-64 age band - each starting from a different evidence base, and each running on a different regulatory clock.

CSL
aTIV / aQIV (FLUAD)
Modeling only - no new RCT in 50-64. Extrapolates the established 65+ effectiveness advantage using a CDC-based compartmental model.
Evidence: modeled Publication-led argument. No active FDA/EMA filing for 50-64 identified.
MRNA
mRNA-1010 (mFLUSIVA)
Split regulatory path: traditional approval for 50-64 built on direct efficacy; accelerated approval for 65+ leaning on immunogenicity.
Decision: 5 Aug 2026 VRBPAC voted 9-0 that benefits outweigh risks for adults 50+. PDUFA action date is imminent.
SNY
Fluzone High-Dose / Efluelda
Completed head-to-head Phase 3 RCT (NCT06641180) vs. standard-dose in ages 50-64 - the strongest primary evidence of the three.
Decision: ~2027 FDA & EMA accepted the submission for review in Q1 2026; company guidance points to a 2027 decision.
One reveal Evidence strength and approval speed are running in opposite directions. Sanofi holds the strongest primary data - an actual randomized trial in 50-64 - yet its regulatory clock runs slowest of the three.
MarketVIEW · Seasonal influenza vaccines · CAT VAMV036

The full modeling - and the wider adjuvanted-vaccine forecast

This is one modeled study inside a fast-moving market. The live MarketVIEW model tracks the adjuvanted and high-dose influenza vaccine landscape, the mRNA-1010 regulatory path, and the global seasonal influenza value & volume forecast to 2040. Excel forecast + executive presentation, updated for 2026.

View the seasonal influenza report ← Back to homepage